Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319862.
- Also identified by DOI 10.1056/EVIDe2200165.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapeutic options for myelodysplastic syndromes (MDS) are highly risk stratified, with more toxic treatments reserved for patients at higher risk and more supportive approaches favored for those with lower-risk disease.<sup>1,2</sup> The hypomethylating agents azacitidine (AZA) and decitabine (DEC) are recommended as first-line therapy for higher-risk MDS; for lower-risk disease, the focus is primarily on treating symptomatic anemia with hematopoietic growth factors, luspatercept, or lenalidomide.
Medical subject headings
- Myelodysplastic Syndromes
- Anemia